When combined with Everolimus or ATP-competitive inhibitors, the Bruton's tyrosine kinase (BTK) inhibitor (Ibrutinib) induces a synergistic effect on cell death in in vitro cultures of human ABC-DLBCL cell lines (146, 147). Here, BTK is linked to diffuse large B-cell lymphoma.